Fludarabine phosphate 25 mg/ml Concentrate for Solution for Injection or Infusion
Sponsors
Allogene Therapeutics Inc., Iovance Biotherapeutics Inc., Prinses Maxima Centrum voor Kinderoncologie B.V., Kite Pharma Inc., St. Anna Childrens Cancer Research Institute GmbH
Conditions
Acute Lymphocytic LeukemiaAcute Myeloid LeukemiaLangerhans Cell HistiocytosisLarge B-Cell Lymphoma (LBCL)MelanomaMetastatic Non-Small-Cell Lung CancerMixed Phenotype Acute LeukemiaNeoplasm
Phase 1
Phase 2
A Single-Arm, Open-Label, Phase 1/2 Study Evaluating the Safety, Efficacy, and Cellular Kinetics/Pharmacodynamics of ALLO-501A, an Anti-CD19 Allogeneic CAR T Cell Therapy, and ALLO-647, an Anti-CD52 Monoclonal Antibody, in Subjects with Relapsed/Refractory Large B Cell Lymphoma (LBCL).
CompletedCTIS2022-501927-25-00
Start: 2023-09-29End: 2024-01-12Target: 35Updated: 2024-01-15
A Randomized, Open-Label, Phase 2 Study Evaluating Lymphodepletion With Fludarabine, Cyclophosphamide, And ALLO-647, Vs. Fludarabine And Cyclophosphamide Alone, In Subjects With Relapsed/Refractory Large B-Cell Lymphoma (LBCL) Receiving ALLO-501A Allogeneic CAR T Cell Therapy
CompletedCTIS2023-503830-27-00
Start: 2023-10-17End: 2024-10-28Target: 35Updated: 2024-01-29
A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-X19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (ZUMA-2)
CompletedCTIS2023-506641-35-00
Start: 2018-07-09End: 2025-06-17Target: 68Updated: 2025-03-10
A Phase 2 Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients with Metastatic Non-Small-Cell Lung Cancer
RecruitingCTIS2024-510778-26-00
Start: 2025-12-19Target: 115Updated: 2025-11-26
A Phase 2 Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients with Metastatic Non-Small-Cell Lung Cancer
RecruitingCTIS2024-510778-26-00
Start: 2025-12-19Target: 115Updated: 2025-11-26
A Phase 2, Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN-144/LN-145/LN-145-S1) in Patients with Solid Tumors
Active, not recruitingCTIS2024-510779-39-00
Start: 2018-12-19Target: 95Updated: 2026-01-21
LCH-IV International Collaborative Treatment Protocol for Children and Adolescents with Langerhans Cell Histiocytosis
Not yet recruitingCTIS2024-512676-36-00
Target: 1124Updated: 2024-10-14
Phase 3
A Phase 3, multicenter, randomized, open-label, parallel group, treatment study to assess the efficacy and safety of the lifileucel (LN-144, autologous tumor-infiltrating lymphocytes [TIL]) regimen in combination with pembrolizumab compared with pembrolizumab monotherapy in participants with untreated, unresectable or metastatic melanoma
RecruitingCTIS2022-503140-41-00
Start: 2024-11-29Target: 280Updated: 2025-10-31
A Phase 3, multicenter, randomized, open-label, parallel group, treatment study to assess the efficacy and safety of the lifileucel (LN-144, autologous tumor-infiltrating lymphocytes [TIL]) regimen in combination with pembrolizumab compared with pembrolizumab monotherapy in participants with untreated, unresectable or metastatic melanoma
RecruitingCTIS2022-503140-41-00
Start: 2024-11-29Target: 280Updated: 2025-10-31